Ductal Carcinoma in Situ - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: DBD6A2A6E994EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Ductal Carcinoma in Situ - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Ductal Carcinoma in Situ epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Ductal Carcinoma in Situ Understanding

The DelveInsight Ductal Carcinoma in Situ epidemiology report gives a thorough understanding of the Ductal Carcinoma in Situ by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Ductal Carcinoma in Situ in the US, Europe, and Japan. The report covers the detailed information of the Ductal Carcinoma in Situ epidemiology scenario in seven major countries (US, EU5, and Japan).

Ductal Carcinoma in Situ Epidemiology Perspective by DelveInsight

The Ductal Carcinoma in Situ epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Ductal Carcinoma in Situ epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Ductal Carcinoma in Situ epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Ductal Carcinoma in Situ Detailed Epidemiology Segmentation

The Ductal Carcinoma in Situ epidemiology covered in the report provides historical as well as forecasted Ductal Carcinoma in Situ epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Ductal Carcinoma in Situ report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Ductal Carcinoma in Situ report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Ductal Carcinoma in Situ Epidemiology Report and Model provide an overview of the global trends of Ductal Carcinoma in Situ in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Ductal Carcinoma in Situ in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Ductal Carcinoma in Situ
• The report provides the segmentation of the Ductal Carcinoma in Situ epidemiology

Report Highlights

• 11-year Forecast of Ductal Carcinoma in Situ epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Ductal Carcinoma in Situ
• Cases of Ductal Carcinoma in Situ by Mutation Types
• Ductal Carcinoma in Situ Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Ductal Carcinoma in Situ?
• What are the key findings pertaining to the Ductal Carcinoma in Situ epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Ductal Carcinoma in Situ across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Ductal Carcinoma in Situ?
• What are the currently available treatments of Ductal Carcinoma in Situ?

Reasons to buy

The Ductal Carcinoma in Situ Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Ductal Carcinoma in Situ market
• Quantify patient populations in the global Ductal Carcinoma in Situ market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Ductal Carcinoma in Situ therapeutics in each of the markets covered
• Understand the magnitude of Ductal Carcinoma in Situ population by its epidemiology
• The Ductal Carcinoma in Situ Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF DUCTAL CARCINOMA IN SITU

3. DUCTAL CARCINOMA IN SITU: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Ductal Carcinoma in Situ Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Ductal Carcinoma in Situ Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Ductal Carcinoma in Situ Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Ductal Carcinoma in Situ Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Ductal Carcinoma in Situ Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Ductal Carcinoma in Situ Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Ductal Carcinoma in Situ Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Ductal Carcinoma in Situ Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Ductal Carcinoma in Situ Treatment and Management
6.2. Ductal Carcinoma in Situ Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Ductal Carcinoma in Situ Epidemiology in 7MM (2019-2032)
Table 2: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Ductal Carcinoma in Situ Epidemiology in the United States (2019-2032)
Table 4: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Ductal Carcinoma in Situ Epidemiology in Germany (2019-2032)
Table 6: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Ductal Carcinoma in Situ Epidemiology in France (2019-2032)
Table 8: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Ductal Carcinoma in Situ Epidemiology in Italy (2019-2032)
Table 10: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Ductal Carcinoma in Situ Epidemiology in Spain (2019-2032)
Table 12: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Ductal Carcinoma in Situ Epidemiology in the United Kingdom (2019-2032)
Table 14: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Ductal Carcinoma in Situ Epidemiology in Japan (2019-2032)
Table 16: Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Ductal Carcinoma in Situ Epidemiology in 7MM (2019-2032)
Figure 2 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Ductal Carcinoma in Situ Epidemiology in the United States (2019-2032)
Figure 4 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Ductal Carcinoma in Situ Epidemiology in Germany (2019-2032)
Figure 6 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Ductal Carcinoma in Situ Epidemiology in France (2019-2032)
Figure 8 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Ductal Carcinoma in Situ Epidemiology in Italy (2019-2032)
Figure 10 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Ductal Carcinoma in Situ Epidemiology in Spain (2019-2032)
Figure 12 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Ductal Carcinoma in Situ Epidemiology in the United Kingdom (2019-2032)
Figure 14 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Ductal Carcinoma in Situ Epidemiology in Japan (2019-2032)
Figure 16 Ductal Carcinoma in Situ Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report